A study has found that oral chronic hepatitis B treatment is effective in curing non-alcoholic fatty liver disease. Patients with non-alcoholic fatty liver disease, where fat builds up in the liver even without drinking alcohol, are increasing due to a western diet and lack of exercise, but there is no approved treatment yet.
Catholic University of Korea St Mary’s Hospital Gastroenterology Professor Seong Pil-soo and Biomedical Health Sciences researcher Purun Noh’s research team announced that they have confirmed that tenofovir alafenamide (TAF) is effective in curing non-alcoholic fatty liver through mice experiments big
Tenofovir alafenamide is a new targeted product of tenofovir, which was first approved in the United States in 2016 as an oral treatment for adults with chronic hepatitis B. A prodrug is a drug that exhibits medicinal effects when it is metabolized by metabolic enzymes when it enters the body. This drug delivers active ingredients to liver cells more efficiently than existing chronic hepatitis B drugs.
As a result of the study, systemic drug exposure in plasma was reduced by approximately 89% and kidney and bone safety was improved. Professor Sung’s team confirmed that blood ALT (alanine aminotransferase) and AST (aspartate aminotransferase) levels improved and liver cell damage decreased when tenofovir alafenamide was administered. In addition, for the first time, it was noted that tenofovir alafenamide inhibits the activation of AKT protein in hepatocytes (mononuclear phagocytes in the liver) to have an anti-inflammatory effect and improve non-alcoholic fatty liver disease.
Professor Seong said, “This study provides a theoretical basis to explain that tenofovir alafenamide has a significantly higher liver function normalization rate than other antiviral drugs.” As there is no drug, patients are advised to lose weight vigorously, eat properly, and do aerobics. physical education. If a standard treatment is established through this study, it will be possible to prevent non-alcoholic fatty liver disease from progressing to severe liver disease.” The results of this study were published in the international journal ‘Biomedicine and Pharmacotherapy’.
Reporter Jeong Jin-soo
[ⓒ 세계일보 & Segye.com, 무단전재 및 재배포 금지]
